TEGSEDI
Peakinotersen sodium
NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Oct 2018
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 52m ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEGSEDI (inotersen sodium) is an antisense oligonucleotide administered subcutaneously for the treatment of hereditary transthyretin (hATTR) amyloidosis. It reduces transthyretin production by targeting TTR mRNA, slowing disease progression in patients with polyneuropathy.
$0.006BPart D
Peak4.5 years to LOEProduct is at peak lifecycle maturity with modest Medicare utilization; commercial team size likely stable with focus on market penetration in rare disease segment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.